Thursday, December 18, 2008

Failure rates in Pharma trials

Thought I'd paste this. Preclinical and Phase I failure rates should have been much higher. Or maybe we have to change trial design in both these phases. Then we'd be able to optimize venture financing and significantly improve venture returns. Phase II and III for Oncology are typically higher than for other drugs which is is equally unfortunate.

Preclinical: 65%
Phase I: 30%
Phase 2: 55%
Phase 3: 40%
Phase 4: 20%

Sent via BlackBerry by AT&T

No comments: